MARY QUIHUIS: Open Payments
NPI 1306978333 · CHANDLER, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$531 in 29 payments from 16 companies in 2025. Trend: 2023 $882 · 2024 $1,100 · 2025 $531
Food & beverage: $531
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 6 | $95 |
| ABBVIE INC. | 3 | $64 |
| Axsome Therapeutics, Inc. | 1 | $54 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $46 |
| GlaxoSmithKline, LLC. | 2 | $40 |
| AstraZeneca Pharmaceuticals LP | 2 | $30 |
| PFIZER INC. | 2 | $29 |
| Daiichi Sankyo Inc. | 2 | $28 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $25 |
| Astellas Pharma US Inc | 1 | $24 |
Products named: VRAYLAR, Auvelity, JARDIANCE, TRELEGY ELLIPTA, Rybelsus, Ozempic, INJECTAFER, CAPLYTA.
Industry payments across AZ — which companies pay providers there.
